Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Jul 23;14(1):16917.
doi: 10.1038/s41598-024-67791-3.

The status and influencing factors of COVID-19 vaccination in patients with COPD

Mingzhe Li #  1 , Qiang Zhang #  1 , Yuanyi Yue #  2 , Zhong He #  1 , Jianwei Fang #  3 , Rui Zheng  4
Affiliations

The status and influencing factors of COVID-19 vaccination in patients with COPD

Mingzhe Li et al. Sci Rep. .

Abstract

In this study, we investigated the status and influencing factors of coronavirus disease 2019 (COVID-19) vaccination in patients with chronic obstructive pulmonary disease (COPD). A questionnaire on COVID-19 vaccination in patients with COPD was developed. The clinical characteristics, COVID-19 vaccination status, other relevant vaccinations, and vaccination status of the patients with COPD were collected anonymously. Logistic regression analysis was used to analyze the factors influencing COVID-19 vaccination in patients with COPD. There were 1898 returned questionnaires, of which 1874 were valid. The proportion of patients who completed the COVID-19 vaccination program was 78.60%. Factors influencing the COVID-19 vaccination rate were: the age of individuals who were 75-85 years old and > 85 years old, acute exacerbation 3-4 times in the previous year, comorbid cardiovascular and endocrine system diseases, failure to take regular medication for COPD, application of non-invasive ventilation machines, believing that their current health condition has deteriorated, believing that the current COVID-19 vaccine is not safe, medical staff not specifying whether they would recommend vaccination against COVID-19, medical staff not recommending the COVID-19 vaccine, and fear of adverse reactions and aggravation of COPD. Patients with COPD had a high COVID-19 vaccination rate in China, whereas patients with pneumonia, influenza, and herpes zoster had a low vaccination rate. Improving the patients' understanding of the safety and effectiveness of the vaccine and promoting effective communication between medical staff and patients would help increase the vaccination rate of patients with COPD.

Keywords: COPD; COVID-19; Influencing factors; Vaccination rate.

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing interests.

Figures

Figure 1
Figure 1
Adverse reactions of influenza, pneumonia, or herpes zoster vaccines in patients with COPD. COPD, chronic obstructive pulmonary disease.
Figure 2
Figure 2
Status of COVID-19 vaccine in patients with COPD and the number of doses. (A) Status of COVID-19 vaccination in patients with COPD; (B) Number of doses of the COVID-19 vaccine in patients with COPD. COPD, chronic obstructive pulmonary disease; COVID-19, coronavirus disease 2019.
Figure 3
Figure 3
Brands and number of COVID-19 vaccinations in patients with COPD. COPD, chronic obstructive pulmonary disease; COVID-19, coronavirus disease 2019.
Figure 4
Figure 4
Occurrence of adverse reactions to COVID-19 vaccine in patients with COPD. COPD, chronic obstructive pulmonary disease; COVID-19, coronavirus disease 2019.
Figure 5
Figure 5
Adverse reactions to COVID-19 vaccine in patients with COPD. COPD, chronic obstructive pulmonary disease; COVID-19, coronavirus disease 2019.
See this image and copyright information in PMC

Similar articles

See all similar articles

References

    1. Sandmann, F. G., Davies, N. G., Vassall, A., Edmunds, W. J. & Jit, M. The potential health and economic value of SARS-CoV-2 vaccination alongside physical distancing in the UK: A transmission model-based future scenario analysis and economic evaluation. Lancet Infect. Dis.21, 962–974. 10.1016/s1473-3099(21)00079-7 (2021). 10.1016/s1473-3099(21)00079-7 - DOI - PMC - PubMed
    1. Schaffer DeRoo, S., Pudalov, N. J. & Fu, L. Y. Planning for a COVID-19 Vaccination Program. JAMA. 323, 2458–2459. 10.1001/jama.2020.8711 (2020). - PubMed
    1. Azoulay, E. et al. Clinical phenotypes of critically ill COVID-19 patients. Intensive Care Med.46, 1651–1652. 10.1007/s00134-020-06120-4 (2020). 10.1007/s00134-020-06120-4 - DOI - PMC - PubMed
    1. Aleva, F. E., van Mourik, L., Broeders, M., Paling, A. J. & de Jager, C. P. C. COVID-19 in critically ill patients in North Brabant, the Netherlands: Patient characteristics and outcomes. J. Crit. Care60, 111–115. 10.1016/j.jcrc.2020.08.001 (2020). 10.1016/j.jcrc.2020.08.001 - DOI - PMC - PubMed
    1. Gujski, M., Jankowski, M., Rabczenko, D., Goryński, P. & Juszczyk, G. Characteristics and clinical outcomes of 116,539 patients hospitalized with COVID-19-Poland, March–December 2020. Viruses. 13. 10.3390/v13081458 (2021). - PMC - PubMed

Substances

LinkOut - more resources